Prophylaxis and treatment of influenza encephalitis in an experimental mouse model

Masayoshi Shinjo(H), Takashi Yoshikawa, Yixing Li, Kyoko Shiraishi, Hideaki Ueki, Kuniaki Nerome

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A mouse model study using mouse brain-adapted influenza A virus was performed to establish the prophylaxis and treatment of influenza encephalitis and encephalopathy. All mice died after intranasal inoculation of the brain-adapted influenza A virus (H7N3), and the pathological findings indicated the presence of significant encephalitis. Viral antigen was also detected in the brain, both pathologically and virologically. By contrast, infected mice immunized with inactivated vaccine of the same strain did not lose weight, which is an indicator of the overall condition of the mice, and all of them survived. Similarly, antiserum treatment in the early period (0-1 day post-infection) resulted in 100% survival, and no pathological findings were observed in the brain. However, mice treated with antiserum 3 days post-infection showed encephalitis with viral antigens in both glial cells and neurocytes. Although amantadine treatment for 4 days delayed weight loss, it did not prevent death from encephalitis. These results show vaccination and early antiserum treatment to be highly effective, whereas 4-day treatment of amantadine was not very effective in treating or preventing influenza encephalitis. The life-prolonging effect of amantadine, however, suggests that use of amantadine together with other treatments may inhibit the progression of encephalitis.

Original languageEnglish
Pages (from-to)406-417
Number of pages12
JournalJournal of Medical Virology
Volume67
Issue number3
DOIs
Publication statusPublished - 2002

Fingerprint

Encephalitis
Human Influenza
Amantadine
Theoretical Models
Immune Sera
Viral Antigens
Influenza A virus
Brain
Therapeutics
Inactivated Vaccines
Brain Diseases
Neuroglia
Weight Loss
Vaccination
Weights and Measures
Infection

Keywords

  • Amantadine
  • Antiserum
  • Influenza virus
  • Mouse
  • Vaccine

ASJC Scopus subject areas

  • Virology

Cite this

Prophylaxis and treatment of influenza encephalitis in an experimental mouse model. / Shinjo(H), Masayoshi; Yoshikawa, Takashi; Li, Yixing; Shiraishi, Kyoko; Ueki, Hideaki; Nerome, Kuniaki.

In: Journal of Medical Virology, Vol. 67, No. 3, 2002, p. 406-417.

Research output: Contribution to journalArticle

Shinjo(H), Masayoshi ; Yoshikawa, Takashi ; Li, Yixing ; Shiraishi, Kyoko ; Ueki, Hideaki ; Nerome, Kuniaki. / Prophylaxis and treatment of influenza encephalitis in an experimental mouse model. In: Journal of Medical Virology. 2002 ; Vol. 67, No. 3. pp. 406-417.
@article{5dbb45a44c894028b8a64d6f6ec6e0cc,
title = "Prophylaxis and treatment of influenza encephalitis in an experimental mouse model",
abstract = "A mouse model study using mouse brain-adapted influenza A virus was performed to establish the prophylaxis and treatment of influenza encephalitis and encephalopathy. All mice died after intranasal inoculation of the brain-adapted influenza A virus (H7N3), and the pathological findings indicated the presence of significant encephalitis. Viral antigen was also detected in the brain, both pathologically and virologically. By contrast, infected mice immunized with inactivated vaccine of the same strain did not lose weight, which is an indicator of the overall condition of the mice, and all of them survived. Similarly, antiserum treatment in the early period (0-1 day post-infection) resulted in 100{\%} survival, and no pathological findings were observed in the brain. However, mice treated with antiserum 3 days post-infection showed encephalitis with viral antigens in both glial cells and neurocytes. Although amantadine treatment for 4 days delayed weight loss, it did not prevent death from encephalitis. These results show vaccination and early antiserum treatment to be highly effective, whereas 4-day treatment of amantadine was not very effective in treating or preventing influenza encephalitis. The life-prolonging effect of amantadine, however, suggests that use of amantadine together with other treatments may inhibit the progression of encephalitis.",
keywords = "Amantadine, Antiserum, Influenza virus, Mouse, Vaccine",
author = "Masayoshi Shinjo(H) and Takashi Yoshikawa and Yixing Li and Kyoko Shiraishi and Hideaki Ueki and Kuniaki Nerome",
year = "2002",
doi = "10.1002/jmv.10088",
language = "English",
volume = "67",
pages = "406--417",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Prophylaxis and treatment of influenza encephalitis in an experimental mouse model

AU - Shinjo(H), Masayoshi

AU - Yoshikawa, Takashi

AU - Li, Yixing

AU - Shiraishi, Kyoko

AU - Ueki, Hideaki

AU - Nerome, Kuniaki

PY - 2002

Y1 - 2002

N2 - A mouse model study using mouse brain-adapted influenza A virus was performed to establish the prophylaxis and treatment of influenza encephalitis and encephalopathy. All mice died after intranasal inoculation of the brain-adapted influenza A virus (H7N3), and the pathological findings indicated the presence of significant encephalitis. Viral antigen was also detected in the brain, both pathologically and virologically. By contrast, infected mice immunized with inactivated vaccine of the same strain did not lose weight, which is an indicator of the overall condition of the mice, and all of them survived. Similarly, antiserum treatment in the early period (0-1 day post-infection) resulted in 100% survival, and no pathological findings were observed in the brain. However, mice treated with antiserum 3 days post-infection showed encephalitis with viral antigens in both glial cells and neurocytes. Although amantadine treatment for 4 days delayed weight loss, it did not prevent death from encephalitis. These results show vaccination and early antiserum treatment to be highly effective, whereas 4-day treatment of amantadine was not very effective in treating or preventing influenza encephalitis. The life-prolonging effect of amantadine, however, suggests that use of amantadine together with other treatments may inhibit the progression of encephalitis.

AB - A mouse model study using mouse brain-adapted influenza A virus was performed to establish the prophylaxis and treatment of influenza encephalitis and encephalopathy. All mice died after intranasal inoculation of the brain-adapted influenza A virus (H7N3), and the pathological findings indicated the presence of significant encephalitis. Viral antigen was also detected in the brain, both pathologically and virologically. By contrast, infected mice immunized with inactivated vaccine of the same strain did not lose weight, which is an indicator of the overall condition of the mice, and all of them survived. Similarly, antiserum treatment in the early period (0-1 day post-infection) resulted in 100% survival, and no pathological findings were observed in the brain. However, mice treated with antiserum 3 days post-infection showed encephalitis with viral antigens in both glial cells and neurocytes. Although amantadine treatment for 4 days delayed weight loss, it did not prevent death from encephalitis. These results show vaccination and early antiserum treatment to be highly effective, whereas 4-day treatment of amantadine was not very effective in treating or preventing influenza encephalitis. The life-prolonging effect of amantadine, however, suggests that use of amantadine together with other treatments may inhibit the progression of encephalitis.

KW - Amantadine

KW - Antiserum

KW - Influenza virus

KW - Mouse

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0036274005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036274005&partnerID=8YFLogxK

U2 - 10.1002/jmv.10088

DO - 10.1002/jmv.10088

M3 - Article

C2 - 12116035

AN - SCOPUS:0036274005

VL - 67

SP - 406

EP - 417

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 3

ER -